SCANCELL

USING IMMUNOLOGY TO FIGHT CANCER

AIM-listed clinical stage biotech company

AGM Presentation

November 6th 2012

Clinical Stage DNA Cancer Vaccines

SCANCELL

USING IMMUNOLOGY TO FIGHT CANCER

Disclaimer

These presentation materials have been prepared by and are the sole responsibility of the directors of Scancell Holdings plc.

These presentation materials do not constitute or form part of any offer for sale or subscription or any solicitation for any offer to buy or subscribe for any securities, nor shall they (or any part of them) form the basis of or be relied upon in connection with any contract or commitment whatsoever. While all reasonable care has been taken to ensure that the facts stated in these presentation materials are accurate and that any forecasts, opinions and expectations contained therein are fair and reasonable, no reliance whatsoever should be placed on them. Accordingly, no representation, undertaking or warranty express or implied is made to the fairness, accuracy, completeness or correctness of these materials or opinions contained therein and each recipient of these presentation materials must make its own investigation and assessment of the matters contained therein. In particular, but without prejudice to the generality of the foregoing, no representation, undertaking or warranty is given, and no responsibility or liability is accepted, as to the achievement or reasonableness of any future projections or the assumptions underlying them, or any forecasts, estimates, or statements as to prospects contained or referred to in these presentation materials. No responsibility or liability whatsoever is accepted by any person for any loss howsoever arising from any use of, or in connection with, these presentation materials or their contents or otherwise arising in connection therewith. In issuing these presentation materials, the Company does not undertake any obligation to update or to correct any inaccuracies which may become apparent in these presentation materials. These presentation materials are being supplied to you for your own information and may not be distributed, published, reproduced or otherwise made available to any other person, in whole or in part, for any purposes whatsoever..

Recipients or readers of these presentation materials are recommended to seek their own independent legal and investment advice. Neither the receipt of these presentation materials, nor any information contained therein or supplied with these presentation materials or subsequently communicated to any person in connection with these presentation materials either constitutes, or is to be taken as constituting, the giving of investment advice by the Company to any person.

Highlights

- Scancell has two flexible platforms for developing novel therapeutic cancer vaccines
  - ImmunoBody® (DNA vaccines)
  - Moditope™ (peptide vaccines)
- Phase 1/2 Clinical PoC data on ImmunoBody® being generated by SCIB1
  - Part 1 data by YE2012
  - Part 2 data by YE2013 (12 (11 evaluable)/13 patients recruited)
- Development of a series of ImmunoBody® vaccines in other cancer indications starting with SCIB2 (lung ,oesophageal, prostate, liver, gastric, ovarian, bladder cancers)
- Actively evaluating strategic options for Moditope™ to maximise shareholder value
- On schedule to complete ongoing clinical programme and position the company or IB assets for sale end 2013/early 2014

The potential of therapeutic cancer vaccines

- Powerful immune response targeted to cancer cells
- Avoidance of normal cells may result in benign side effect profile
- Disease stabilisation, control and potential cure
- Survival benefit
- Turning cancer into a long term chronic disease

Cancer vaccine newsflow

Significant near-term newsflow expected

Product	Indication	Phase	Event	Timing
Allovectin (Vical)	Stage 3 or Stage 4 Melanoma	Phase III	Topline results for primary (response rate) and secondary (OS) endpoints	Late 2012/Early 2013
Lucanix (NovaRx Corporation)	Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)	Phase III	Second interim analysis	4Q12
OncoVEX (Amgen)	Stage IIIb, IIIc or stage IV melanoma	Phase III	Estimated primary completion date (clinicaltrials.gov)	Jan-13
Stimuvax (Oncothyreon/ Merck)	Stage III Non-small Cell Lung Cancer	Phase III	Estimated primary completion date (clinicaltrials.gov)	Feb-13
DCVax(R)-L (Northwest Biotherapeutics)	Newly diagnosed Glioblastoma Multiforme	Phase III	Estimated primary completion date (clinicaltrials.gov)	Jun-13
TVI-Brain-1 (TVAX)	Recurrent glioblastomas	Phase II	Estimated primary completion date (clinicaltrials.gov)	Dec-13
GSK 2132231A (GSK)	Resected Stage III Melanoma, NSCLC	Phase III	Topline results	2013

Source: company reports, clinicaltrials.gov

What is ImmunoBody® platform

Key advantages of ImmunoBody® Technology:

- Generate potent T cell responses that kill tumour cells, inhibit the growth of solid tumours and prevent the spread of metastatic disease
- Low cost, rapid and easy generic manufacturing process
- Platform can deliver multiple drugs
- Rapid target validation
- High predictive success rate for new targets

SCIB1 (DNA vaccine for Melanoma)

- Induces powerful anti-tumour activity in vivo
- CTA May 2010
- Phase 1/2 Clinical Trial started June 2010
- Part 1 results 4Q12
- Part 2 started 2Q12
- Part 2 results 2013

12 (11 evaluable)/13 patients now recruited



SCANCELL
USING IMMUNOLOGY TO FIGHT CANCER

Phase 1/2 trial in stage III/IV melanoma

Primary Objective: To demonstrate safety and tolerability

Secondary Objective: To demonstrate cellular immune response (high avidity T-cells) and tumour response

Part One

- 9 patients
- 3 subjects per cohort; 0.4mg, 2.0 mg or 4.0 mg
- Progression only if adequate safety demonstrated at previous dose
- 5 vaccinations at start, 3 weeks, 6 weeks, 3 months and 6 months
- PRELIMINARY RESULTS TO BE REPORTED 4Q12

Part Two

- 13 subjects to receive 4mg dose
- Recruitment started 2Q12
- 12 (11 evaluable) /13 patients already recruited

Approval to treat patients for up to 5 years granted in June 2012